|Videos|May 20, 2021
The Ever-Expanding Multiple Sclerosis Therapeutics
Join Ahmed Obeidat, MD, PhD; Mitchell Freedman, MD; and Suma Shah, MD, for the second program of this monthly series as they discuss the evolution of therapeutics for the treatment of multiple sclerosis.
Advertisement
————————————
Panelists
- Ahmed Obeidat, MD, PhD
Assistant Professor, Department of Neurology, Neuroimmunology and Multiple Sclerosis; Director, Neuroimmunology and MS Fellowship Program, The Medical College of Wisconsin - Suma Shah, MD
Director, MS & Neuroimmunology Fellowship, Duke University School of Medicine - S. Mitchell Freedman, MD FAAN
Adjunct Professor of Neurology, University of North Carolina-Chapel Hill
Key Learning Objectives
- Virtual patient visits during COVID-19 when treating MS
- Changing barriers to treating MS
- Evolution of monitoring safety and efficacy of therapy
- The future of treating MS
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
- NeurologyLive® Friday 5 — September 12, 2025
September 12th 2025
- Expanding the Alzheimer Drug Development Pipeline
September 12th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive
1
Expanding the Alzheimer Drug Development Pipeline
2
DORAs Carry Lower Real-World Abuse, New Phase 3 Argus Data, RAP-219 Meets Primary End Point
3
MDA and PPMD Release Consensus Guidelines for Safe and Equitable Use of Gene Therapy in Duchenne
4
NeurologyLive® Friday 5 — September 12, 2025
5